AR030364A1 - Compuestos para el tratamiento de desordenes adictivos - Google Patents

Compuestos para el tratamiento de desordenes adictivos

Info

Publication number
AR030364A1
AR030364A1 ARP010103925A ARP010103925A AR030364A1 AR 030364 A1 AR030364 A1 AR 030364A1 AR P010103925 A ARP010103925 A AR P010103925A AR P010103925 A ARP010103925 A AR P010103925A AR 030364 A1 AR030364 A1 AR 030364A1
Authority
AR
Argentina
Prior art keywords
disorders
treatment
addiction
compounds
active
Prior art date
Application number
ARP010103925A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR030364A1 publication Critical patent/AR030364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de cantidad terapéuticamente efectiva, no toxica, de un agente activo seleccionado entre el grupo que consiste de una amina heterocíclica, un fenilazacicloalcano una cabergolina, una amina bicíclica aromática y derivados y sales farmacéuticamente aceptables de cualquiera de dichos agentes activos, para la fabricacion de un medicamento para el tratamiento o supresion de los síntomas de por lo menos un desorden seleccionado entre desordenes activos, desordenes del uso de sustancias psicoactivas, desordenes de intoxicacion , desordenes de inhalacion , adiccion al alcohol, adiccion al tabaco y adiccion a la nicotina, para un paciente que necesita tratamiento.
ARP010103925A 2000-08-16 2001-08-16 Compuestos para el tratamiento de desordenes adictivos AR030364A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22571400P 2000-08-16 2000-08-16
US26361001P 2001-01-23 2001-01-23

Publications (1)

Publication Number Publication Date
AR030364A1 true AR030364A1 (es) 2003-08-20

Family

ID=26919847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103925A AR030364A1 (es) 2000-08-16 2001-08-16 Compuestos para el tratamiento de desordenes adictivos

Country Status (17)

Country Link
US (2) US6841557B2 (es)
EP (1) EP1363634A2 (es)
JP (1) JP2004506621A (es)
KR (1) KR20030024877A (es)
AR (1) AR030364A1 (es)
AU (2) AU2001283393B2 (es)
BR (1) BR0112939A (es)
CA (1) CA2413762A1 (es)
CZ (1) CZ200380A3 (es)
EA (1) EA200300271A1 (es)
IL (1) IL154378A0 (es)
MX (1) MXPA03001472A (es)
NO (1) NO20030717D0 (es)
NZ (1) NZ524741A (es)
PE (1) PE20020288A1 (es)
PL (1) PL363365A1 (es)
WO (1) WO2002013807A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
MXPA05003513A (es) * 2002-10-04 2005-06-03 Pharmacia Corp Composiciones farmaceuticas para tratamiento de enfermedad de parkinson.
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) * 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
WO1992000282A1 (en) * 1990-06-29 1992-01-09 The Upjohn Company Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
JP3176063B2 (ja) 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
TW252979B (es) * 1992-12-24 1995-08-01 Erba Carlo Spa
CN1046723C (zh) * 1993-04-06 1999-11-24 艾博特公司 四环化合物、含有它们的药物组合物及其用途
ATE182590T1 (de) 1993-12-28 1999-08-15 Upjohn Co Heterozyklische verbindungen für die behandlung von kardiovaskular- und zentralnervensystem störungen
GB9407637D0 (en) * 1994-04-18 1994-06-08 Erba Carlo Spa Serotoninergic abeo-ergoline derivatives
US5874477A (en) * 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9603226D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Heterocyclyl-ergoline derivatives
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US20020010197A1 (en) * 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
CA2405565A1 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome

Also Published As

Publication number Publication date
PL363365A1 (en) 2004-11-15
JP2004506621A (ja) 2004-03-04
EP1363634A2 (en) 2003-11-26
NZ524741A (en) 2005-01-28
KR20030024877A (ko) 2003-03-26
WO2002013807A2 (en) 2002-02-21
AU2001283393B2 (en) 2005-09-22
NO20030717L (no) 2003-02-14
BR0112939A (pt) 2005-11-01
US20020049206A1 (en) 2002-04-25
IL154378A0 (en) 2003-09-17
EA200300271A1 (ru) 2004-02-26
MXPA03001472A (es) 2003-06-06
CA2413762A1 (en) 2002-02-21
PE20020288A1 (es) 2002-03-31
US20030078273A1 (en) 2003-04-24
WO2002013807A3 (en) 2003-09-25
AU8339301A (en) 2002-02-25
NO20030717D0 (no) 2003-02-14
US6841557B2 (en) 2005-01-11
CZ200380A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
BR0107983A (pt) Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
GT200000041A (es) Uso de inhibidores de cyp2d6 en terapias de combinacion.
MXPA04004173A (es) Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
PA8591701A1 (es) Derivados de pirrolopirimidina
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
AU778092B2 (en) Pharmaceutical formulations containing zolmitriptan
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
HUP0300048A2 (hu) Transzdermális vagy transzmukozális dohányzásról leszoktató készítmények, melyek nikotintartalmú hatóanyagkombinációt tartalmaznak és alkalmazásuk
AR030364A1 (es) Compuestos para el tratamiento de desordenes adictivos
PT1069900E (pt) Novos tratamentos para disturbios nervosos
BRPI0417350A2 (pt) composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
CO5700713A2 (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion a nicotina en un mamifero
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
AR016308A1 (es) Uso de inhibidores de la fosfodiesterasa 4 o sus sales, medicamento para el tratamiento de la rinitis alergica que contiene los compuestos mencionados yprocedimiento para preparar dicho medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure